Concise review: Optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications

Allison I. Hoch, Jonathan K Leach

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Bone marrow-derived mesenchymal stem/stromal cells (MSCs) have demonstrated success in the clinical treatment of hematopoietic pathologies and cardiovascular disease and are the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and nervous systems. However, during the requisite two-dimensional (2D) expansion to achieve a clinically relevant number of cells, MSCs exhibit profound degeneration in progenitor potency. Proliferation, multilineage potential, and colony-forming efficiency are fundamental progenitor properties that are abrogated by extensive monolayer culture. To harness the robust therapeutic potential of MSCs, a consistent, rapid, and minimally detrimental expansion method is necessary. Alternative expansion efforts have exhibited promise in the ability to preserve MSC progenitor potency better than the 2D paradigm by mimicking features of the native bone marrow niche. MSCs have been successfully expanded when stimulated by growth factors, under reduced oxygen tension, and in three-dimensional bioreactors. MSC therapeutic value can be optimized for clinical applications by combining system inputs to tailor culture parameters for recapitulating the niche with probes that nondestructively monitor progenitor potency. The purpose of this review is to explore how modulations in the 2D paradigm affect MSC progenitor properties and to highlight recent efforts in alternative expansion techniques.

Original languageEnglish (US)
Pages (from-to)643-652
Number of pages10
JournalStem cells translational medicine
Volume3
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Mesenchymal Stromal Cells
Integumentary System
Bone Marrow
Digestive System
Musculoskeletal System
Bioreactors
Nervous System
Intercellular Signaling Peptides and Proteins
Cardiovascular Diseases
Cell Count

Keywords

  • Bioreactor
  • Expansion
  • Growth factor
  • Hypoxia
  • Mesenchymal stromal/stem cell
  • Progenitor

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Concise review : Optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications. / Hoch, Allison I.; Leach, Jonathan K.

In: Stem cells translational medicine, Vol. 3, No. 5, 2014, p. 643-652.

Research output: Contribution to journalArticle

@article{58f269cf0d434026b6adfdbb2ff63345,
title = "Concise review: Optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications",
abstract = "Bone marrow-derived mesenchymal stem/stromal cells (MSCs) have demonstrated success in the clinical treatment of hematopoietic pathologies and cardiovascular disease and are the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and nervous systems. However, during the requisite two-dimensional (2D) expansion to achieve a clinically relevant number of cells, MSCs exhibit profound degeneration in progenitor potency. Proliferation, multilineage potential, and colony-forming efficiency are fundamental progenitor properties that are abrogated by extensive monolayer culture. To harness the robust therapeutic potential of MSCs, a consistent, rapid, and minimally detrimental expansion method is necessary. Alternative expansion efforts have exhibited promise in the ability to preserve MSC progenitor potency better than the 2D paradigm by mimicking features of the native bone marrow niche. MSCs have been successfully expanded when stimulated by growth factors, under reduced oxygen tension, and in three-dimensional bioreactors. MSC therapeutic value can be optimized for clinical applications by combining system inputs to tailor culture parameters for recapitulating the niche with probes that nondestructively monitor progenitor potency. The purpose of this review is to explore how modulations in the 2D paradigm affect MSC progenitor properties and to highlight recent efforts in alternative expansion techniques.",
keywords = "Bioreactor, Expansion, Growth factor, Hypoxia, Mesenchymal stromal/stem cell, Progenitor",
author = "Hoch, {Allison I.} and Leach, {Jonathan K}",
year = "2014",
doi = "10.5966/sctm.2013-0196",
language = "English (US)",
volume = "3",
pages = "643--652",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Concise review

T2 - Optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications

AU - Hoch, Allison I.

AU - Leach, Jonathan K

PY - 2014

Y1 - 2014

N2 - Bone marrow-derived mesenchymal stem/stromal cells (MSCs) have demonstrated success in the clinical treatment of hematopoietic pathologies and cardiovascular disease and are the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and nervous systems. However, during the requisite two-dimensional (2D) expansion to achieve a clinically relevant number of cells, MSCs exhibit profound degeneration in progenitor potency. Proliferation, multilineage potential, and colony-forming efficiency are fundamental progenitor properties that are abrogated by extensive monolayer culture. To harness the robust therapeutic potential of MSCs, a consistent, rapid, and minimally detrimental expansion method is necessary. Alternative expansion efforts have exhibited promise in the ability to preserve MSC progenitor potency better than the 2D paradigm by mimicking features of the native bone marrow niche. MSCs have been successfully expanded when stimulated by growth factors, under reduced oxygen tension, and in three-dimensional bioreactors. MSC therapeutic value can be optimized for clinical applications by combining system inputs to tailor culture parameters for recapitulating the niche with probes that nondestructively monitor progenitor potency. The purpose of this review is to explore how modulations in the 2D paradigm affect MSC progenitor properties and to highlight recent efforts in alternative expansion techniques.

AB - Bone marrow-derived mesenchymal stem/stromal cells (MSCs) have demonstrated success in the clinical treatment of hematopoietic pathologies and cardiovascular disease and are the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and nervous systems. However, during the requisite two-dimensional (2D) expansion to achieve a clinically relevant number of cells, MSCs exhibit profound degeneration in progenitor potency. Proliferation, multilineage potential, and colony-forming efficiency are fundamental progenitor properties that are abrogated by extensive monolayer culture. To harness the robust therapeutic potential of MSCs, a consistent, rapid, and minimally detrimental expansion method is necessary. Alternative expansion efforts have exhibited promise in the ability to preserve MSC progenitor potency better than the 2D paradigm by mimicking features of the native bone marrow niche. MSCs have been successfully expanded when stimulated by growth factors, under reduced oxygen tension, and in three-dimensional bioreactors. MSC therapeutic value can be optimized for clinical applications by combining system inputs to tailor culture parameters for recapitulating the niche with probes that nondestructively monitor progenitor potency. The purpose of this review is to explore how modulations in the 2D paradigm affect MSC progenitor properties and to highlight recent efforts in alternative expansion techniques.

KW - Bioreactor

KW - Expansion

KW - Growth factor

KW - Hypoxia

KW - Mesenchymal stromal/stem cell

KW - Progenitor

UR - http://www.scopus.com/inward/record.url?scp=84899683599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899683599&partnerID=8YFLogxK

U2 - 10.5966/sctm.2013-0196

DO - 10.5966/sctm.2013-0196

M3 - Article

C2 - 24682286

AN - SCOPUS:84899683599

VL - 3

SP - 643

EP - 652

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 5

ER -